Clinical trials: Circulating Tumor DNA
Non Small Cell Lung Cancer, Circulating Tumor Cell
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA
- Trial name
- WHENII (NCT03481101)
- Testing
- PET/CT
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Cancer, Circulating Tumor DNA
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem.
- Conditions
- Pancreatic Cancer, Circulating Tumor DNA, KRAS Mutation-Related Tumors
- Trial name
- NCT04560270
- Testing
- Blood samples
- Volunteers
- 69 people
- Sponsor
- Poitiers University Hospital
Stomach Neoplasms, Circulating Tumor DNA
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
The primary purpose of this trial is to describe the profile of ctDNA methylation in gastric cancer. The second purpose is to demonstrate the correlation between the plasma ctDNA methylation status and the diagnosis and prognosis…
- Trial name
- NCT04511559
- Testing
- Circulating Tumor DNA Methylation Sequencing, tissue DNA Methylation Sequencing
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
HER2-positive Breast Cancer, Chemotherapy Effect
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Locally advanced breast cancer (LABC) is defined as breast cancer (BC) larger than 5 centimeters or with lymph node metastasis. Usually, LABC is treated with neoadjuvant chemotherapy (NAC) followed by curative surgery to reduce…
- Conditions
- HER2-positive Breast Cancer, Chemotherapy Effect, Circulating Tumor DNA
- Trial name
- NCT04276337
- Testing
- LiquidSCAN(Trade Mark) / CancerSCAN(Trade Mark)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Advanced NSCLC, Circulating Tumor Cells
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
- Conditions
- Advanced NSCLC, Circulating Tumor Cells, Circulating Tumor DNA
- Trial name
- NCT04229121
- Testing
- nonintervention
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Rectal Neoplasms, Neoadjuvant Therapy
Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer
Application of circulating tumor DNA detection in diagnosis and treatment of locally advanced rectal cancer. First, to explore the feasibility of ctDNA as a detection index for rectal cancer.
- Conditions
- Rectal Neoplasms, Neoadjuvant Therapy, Circulating Tumor DNA
- Trial name
- NCT03615170
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Neoadjuvant Chemotherapy
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the…
- Conditions
- Breast Cancer, Neoadjuvant Chemotherapy, Circulating Tumor DNA
- Trial name
- NCT03688035
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zhiyong Yu
Circulating Tumor DNA, Cancer
Concordance Between ctDNA Assay and FoundationOne
Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has…
- Conditions
- Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing
- Trial name
- NCT02620527
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Foundation Medicine
To Compare the Monitoring of Circulating Tumor DNA With the Efficacy of Chemotherapy Evaluated by Computer Tomography Scan.
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment
Colorectal cancer (CRC) is the third of the most common cancers and the second leading cause of cancer death in western countries.
- Trial name
- NCT01983098
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris